Juliane Bernholz, PhD
Chief Executive Officer
Dr. Juliane Bernholz is an experienced CEO, cell biologist, and molecular geneticist with 30 years of leadership experience in the pharmaceutical industry having worked and lived in the US and multiple countries in Europe. Currently, she serves as the CEO of AM-Pharma, a private clinical stage biotech company located in the Netherlands, where she has been instrumental in developing innovative medicines for patients confronted with severe medical conditions. Prior to Dr. Bernholz’ role at AM-Pharma, she held senior leadership positions in R&D and Business Development at renowned companies such as Johnson&Johnson, Sanofi, Novartis and Actelion.
Throughout her career, Dr. Bernholz has successfully led cross-functional high performing teams, managed complex global drug development programs from discovery through registration, has driven strategic initiatives across small molecules, biologics, new modalities and cutting-edge therapies and has played a key role in bringing multiple therapies to market and optimizing portfolios. Furthermore, she has successfully raised funds and negotiated, executed and chaired collaborations with industry and academia.
With a strong foundation in scientific research, having worked under Nobel laureates and completed a PhD in Cell Biology, Dr. Bernholz is passionate about leveraging scientific innovation to improve patient outcomes. She has completed executive leadership programs at Wharton and IMD including a Board Director Diploma.
Dr. Bernholz is dedicated to fostering collaboration and driving growth in the global pharmaceutical sector.
Outside of work, she enjoys exploring diverse cultures, nature, and outdoor activities such as swimming, tennis, hiking and skiing. Dr. Bernholz has two grown-up sons.
